DepoMed, Inc. (NASDAQ:DEPO)

CAPS Rating: 3 out of 5

A specialty pharmaceutical company focused on the development and commercialization of differentiated products that address growing markets and are based on proprietary oral drug delivery technologies.

Results 1 - 20 of 36 : 1 2 Next »

Recs

0
Member Avatar TrackMagicFormul (85.52) Submitted: 10/8/2014 10:01:14 AM : Outperform Start Price: $10.82 DEPO Score: +38.67

Investors should consider selling puts. You can achieve some very high annualized returns at strikes significantly below the current price. e.g.

Mar 15 $13.00 strike at $1.45 has 20% discount and 24% annualized return.

Recs

0
Member Avatar TMFfoolish1 (62.40) Submitted: 9/8/2014 1:58:24 PM : Underperform Start Price: $14.05 DEPO Score: -9.61

Head and shoulder reversal pattern. Price will probably work against the market in the next few months.

Recs

0
Member Avatar Kenji94 (24.87) Submitted: 8/13/2014 8:33:22 AM : Outperform Start Price: $12.28 DEPO Score: +21.84

Small undervalued stock with tremendous growth prospects.

Recs

0
Member Avatar Crystalball (78.91) Submitted: 3/13/2014 11:52:12 AM : Outperform Start Price: $14.84 DEPO Score: -2.63

Revenues continue to increase for Gralise and Zipsor, company expects total revenue to increase by over 400% just this year. Nice pipeline, Lazanda for cancer patients has huge potential in and of itself. Rare to find a company doing everything right. What is even more impressive is DEPO severely undervalued compared to its peers in the space. Not everyday one can have a 10x bagger -- but nice chance of that happening with DEPO in 2014.

Recs

0
Member Avatar cavemantrader (57.68) Submitted: 12/18/2013 12:43:39 PM : Outperform Start Price: $9.37 DEPO Score: +50.38

Cambia is an NSAID, or non-steroidal anti-inflammatory drug, that is used to treat migraine attacks in adults. The acquisition will substantially boost DepoMed's pain and neurology offerings, since it is the only approved NSAID in the U.S. specifically indicated as a migraine treatment.

Recs

0
Member Avatar dmsorensen (65.49) Submitted: 12/9/2013 9:47:30 PM : Outperform Start Price: $8.50 DEPO Score: +67.91

Outperform

Recs

0
Member Avatar scrubs62074 (78.95) Submitted: 1/31/2013 3:58:38 PM : Outperform Start Price: $7.01 DEPO Score: +82.72

High vOLUME bREAK OUT 1/31/13

Recs

0
Member Avatar stpatrick31782 (< 20) Submitted: 12/12/2011 1:22:24 PM : Outperform Start Price: $4.49 DEPO Score: +173.47

PEG, P/FCF, analyst, EPS next 5 years.

Recs

1
Member Avatar siri22 (< 20) Submitted: 11/13/2011 4:06:17 PM : Outperform Start Price: $4.80 DEPO Score: +155.65

Hurt bt abt. But graise launch 150m in cash

Recs

1
Member Avatar JackCaps (24.88) Submitted: 8/30/2011 12:28:16 AM : Outperform Start Price: $6.29 DEPO Score: +76.37

DepoMed exhibits revenue growth at a low valuation.

Recs

0
Member Avatar eesirrius (< 20) Submitted: 7/15/2011 10:18:11 AM : Outperform Start Price: $8.39 DEPO Score: +29.98

MFI Screen

Recs

0
Member Avatar pbk100 (29.97) Submitted: 5/20/2011 11:07:05 PM : Outperform Start Price: $8.09 DEPO Score: +37.64

Magic Formula. Insider buying. Plenty of cash and proven ability to bring in money through partnering.

Recs

0
Member Avatar TMFBiologyFool (96.90) Submitted: 2/15/2011 3:14:28 PM : Outperform Start Price: $8.90 DEPO Score: +21.98

Gralise should be able to compete with generics. ER tech should pay dividends down the road.

Recs

1
Member Avatar yazzbro (21.26) Submitted: 2/11/2011 10:39:49 AM : Outperform Start Price: $9.28 DEPO Score: +14.77

This company has several meds in the pipeline. One just got approval(Gralise) and the other med is about to have word on approval for another med(Sereda). It also has a few other meds in the pipeline that are a year away or so. The only thing holding this stock from going to $15 - $20 a share is its contract dispute with Abbott. When that works itself out look for a nice rise in the stock price.

Recs

0
Member Avatar starturn2011 (< 20) Submitted: 1/28/2011 9:05:24 AM : Outperform Start Price: $6.25 DEPO Score: +89.03

DepoMed’s DM-1796 will be FDA approved by or before the end of the month.

Recs

1
Member Avatar RDEPVB (< 20) Submitted: 11/26/2010 9:12:59 AM : Outperform Start Price: $5.37 DEPO Score: +114.23

Proven technology, great pipeline, self financing and 2 potential Billion $ products. Just hope the company doesn't get bought in the next few years.

Recs

1
Member Avatar shagberg (< 20) Submitted: 11/1/2010 10:18:39 AM : Outperform Start Price: $5.03 DEPO Score: +133.46

I like the number and type of products Depomed has in the pipeline. Also the relationships they have with major Pharma. Possible takeover within two years.

Recs

3
Member Avatar yellowear (34.26) Submitted: 5/9/2010 12:29:14 PM : Outperform Start Price: $2.45 DEPO Score: +427.93

When all the bad news is out and the stock has oversold below $2.50, that's when I bought with real money and expect in 5 years to be more than a 5 bagger.

Just about perfect trade!

Recs

0
Member Avatar ecapital (< 20) Submitted: 5/2/2010 10:33:53 AM : Outperform Start Price: $4.04 DEPO Score: +204.70

Great pipeline potential.&lt;br /&gt;Cash flow positive wi 18-24 months.&lt;br /&gt;Huge earnings potential.

Recs

1
Member Avatar ssbb123 (29.78) Submitted: 2/22/2010 3:16:36 PM : Underperform Start Price: $2.46 DEPO Score: -427.13

"Cancer risk" can't see this being a good investment for the next few months at least.
http://www.forbes.com/2010/02/18/xenoport-glaxosmithkline-depomed-markets-equities-pharmaceuticals.html?partner=yahootix

Results 1 - 20 of 36 : 1 2 Next »

Featured Broker Partners


Advertisement